Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A

International Journal of Cancer

Volumn 107, Issue 5, 2003, Pages 721-728

  Woehlecke, Holger ^a   Osada, Hiroyuki ^b   Herrmann, Andreas ^a   Lage, Hermann ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Japan Science and Technology Agency   (Japan)

Author keywords

ABCG2; Atypical multidrug resistance; Chemosensitizer; Diketopiperazine; MDR modulator; MXR

Indexed keywords

ABC TRANSPORTER; ANTIBIOTIC G 418; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DAUNORUBICIN; DOXORUBICIN; ELACRIDAR; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PIPERAZINEDIONE; TRYPROSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; STOMACH CARCINOMA; TREATMENT FAILURE; TUMOR CELL;

ACRIDINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INDOLE ALKALOIDS; KINETICS; MITOXANTRONE; PIPERAZINES; STOMACH NEOPLASMS; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0242300545     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11444     Document Type: Article

References (37)

1. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents, in press.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-depending transporters. Nat Rev Cancer 2002;2:48-58.
3. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40(Suppl):S3-8.
4. Lage H, Dietel M. Effect of the breast cancer resistance protein on atypical multidrug resistance. Lancet Oncol 2000;1:169-75.
5. Borst P, Oude Elferink R. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
6. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999;91: 429-33.
7. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
8. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000;96:365-8.
9. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 2001;115:257-62.
10. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-34.
11. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ ABCP-overexpressing cells. Cancer Res 2001;61:6635-9.
12. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Over-expression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002;62:5035-40.
13. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 2002;1:696-702.
14. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996;32A:1070-81.
15. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16: 3674-90.
16. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000;60:47-50.
17. van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg Med Chem Lett 2001;11:29-32.
18. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-25.
19. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999;146:117-26.
20. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD. Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 2001;61; 739-48.
21. Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001;7:935-41.
22. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, Carminati P, Scheffer GL, et al. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 2001; 61:6034-7.
23. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Estrone and 17β-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 2002;93:231-5.
24. Cui CB, Kakeya H, Okada G, Onose R, Ubukata M, Takahashi I, Isono K, Osada H. Tryprostatins A and B, novel mammalian cell cycle inhibitors produced by Aspergillus fumigatus. J Antibiot 1995;48: 1382-4.
25. Cui CB, Kakeya H, Okada G, Onose R, Osada H. Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. I. Taxonomy, fermentation, isolation and biological properties. J Antibiot 1996;49:527-33.
26. Cui CB, Kakeya H, Osada H. Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. II. Physico-chemical properties and structures. J Anti-biot 1996;49:534-40.
27. Usui T, Kondoh M, Cui CB, Mayumi T, Osada H. Tryprostatin A, a specific and novel inhibitor of microtubule assembly. Biochem J 1998;333:543-8.
28. Dietel M, Arps H, Lage H, Niendorf, A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 1990;50:6100-6.
29. Lage H, Jordan A, Scholz R, Dietel M. Thermosensitivity of multi drug-resistant human gastric and pancreatic carcinoma cells. Int J Hyperthermia 2000;16:291-303.
30. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT. Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990;265:10073-80.
31. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
32. Lage H, Perlitz, C, Abele R, Tampé R, Dietel M, Schadendorf D, Sinha P. Enhanced expression of human ABC-transporter TAP is associated with cellular resistance to mitoxantrone. FEBS Lett 2001; 503:179-84.
33. Lage H, Helmbach H, Grottke C, Dietel M, Schadendorf D. DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett 2001;494:54-9.
34. Kowalski P, Wichert A, Holm PS, Dietel M, Lage H. Selection and characterization of a high activity ribozyme directed against the antineoplastic drug resistance-associated ABC-transporter BCRP/ MXR/ABCG2. Cancer Gene Ther 2001;8:185-92.
35. Kowalski P, Stein U, Scheffer GL, Lage H. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC-transporter BCRP/MXR/ABCG2. Cancer Gene Ther 2002;9:579-86.
36. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-602.
37. Loo TW, Clarke DM. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochim Biophys Acta 1999;1461:315-25.